Long-term therapies for patients with musculoskeletal disease include methotrexate, hydroxychloroquine, and anti-TNF (tumor necrosis factor) agents.15,16 Rituximab showed promising results in treating patients who did not respond to other forms of therapy, especially in granulomatous mass lesions. Here, TNF is linked to musculoskeletal system disorder.